Role of vasoactive drugs in the treatment of bleeding oesophageal varices.
Recent advances in the knowledge of the pathophysiology of portal hypertension has opened new indications for the pharmacologic treatment of acute variceal bleeding. Treatment with vasoactive agents is immediately available, easy to use and can be considered as definitive or adjunctive to endoscopic therapy. The data from randomised trials of vasoactive drug treatment for acute variceal bleeding are reviewed, using meta-analysis where applicable. The use of vasopressin has been decreased as a consequence of its questionable efficacy and its high incidence of side effects. Terlipressin is the only drug that has been shown to improve survival, albeit in small trials and there are insufficient data of its use over 5 days. Somatostatin has been shown to have similar efficacy with terlipressin with significantly less side effects. The demonstrated efficacy of octreotide in acute variceal bleeding is less than terlipressin and somatostatin and it cannot be considered as drug of first choice. Somatostatin combined with sclerotherapy represents the optimal therapy today as this combination has been shown to be more effective than sclerotherapy alone and it is safe given over 5 days.
Goulis
J
J
Liver Transplantation and Hepatobiliary Medicine, Royal Free Hospital, London, UK.
Burroughs
A K
AK
D003131:Combined Modality Therapy; D004932:Esophageal and Gastric Varices / Q000150:complications* / Q000628:therapy; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000628:therapy*; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use*; D015911:Sclerotherapy; D013004:Somatostatin / Q000627:therapeutic use*; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
D006728:Hormones; D014662:Vasoconstrictor Agents; D013004:Somatostatin; D015282:Octreotide